Status:

WITHDRAWN

Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder

Lead Sponsor:

Dennis Charney

Collaborating Sponsors:

National Institutes of Health (NIH)

Conditions:

Major Depressive Disorder

Eligibility:

All Genders

21-55 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to test a candidate drug, Org 24448,in a phase II clinical trial in adult patients with moderately treatment-resistant unipolar major depressive disorder.

Detailed Description

Major depressive disorder (MDD) is a common, severe, chronic and often life-threatening illness. Major depression contributes to significant morbidity and mortality. Available pharmacotherapies for ma...

Eligibility Criteria

Inclusion

  • Clinical Diagnosis of MDD
  • Have not responded to an adequate trial of one antidepressant in the current episode or have not completed antidepressant trials due to intolerance to ≤3 antidepressant medications in the current or a previous episode

Exclusion

  • Presence of psychotic features, OCD, drug or alcohol dependency with the preceding 3 months

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2005

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00262665

Start Date

March 1 2005

End Date

March 1 2005

Last Update

December 11 2012

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder | DecenTrialz